home · filing · 0001513162-22-000139
8-K
filed December 9, 2022, 6:59 PM ET
ticker BMRA
CIK 0000073290
leadership
confidence high
sentiment neutral
materiality 0.30
Director Mark Sirgo steps down; David Moatazedi elected to Biomerica board
BIOMERICA INC
Mark Sirgo left the Board of Directors on December 7, 2022 at the annual shareholder meeting.
Sirgo was not nominated for re-election; his departure was previously announced in proxy materials.
Shareholders elected David Moatazedi to fill the seat vacated by Sirgo.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2022-12-07
Filed December 9, 2022, 6:59 PM ET
At the Annual Shareholder Meeting, shareholders elected Mr. David Moatazedi to fill the seat vacated by Mr. Sirgo.
Effective 2022-12-07
Successor David Moatazedi
Filed December 9, 2022, 6:59 PM ET
On December 7, 2022, at the Company’s Annual Shareholder Meeting, Mr. Mark Sirgo stepped down as a member of the Board of Directors of Biomerica.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Moatazedi was elected as member of the Board of Directors at BIOMERICA INC.
Action elected
Role member of the Board of Directors
Exact text from the filing
At the Annual Shareholder Meeting, shareholders elected Mr. David Moatazedi to fill the seat vacated by Mr. Sirgo.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mark Sirgo departed as member of the Board of Directors at BIOMERICA INC.
Action stepped down
Role member of the Board of Directors
Exact text from the filing
On December 7, 2022, at the Company’s Annual Shareholder Meeting, Mr. Mark Sirgo stepped down as a member of the Board of Directors of Biomerica.
View on SEC.gov
Source: SEC EDGAR
accession 0001513162-22-000139
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.